Compounds > aripiprazole
Page last updated: 2024-08-24

aripiprazole and morphine

aripiprazole has been researched along with morphine in 7 studies

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (57.14)29.6817
2010's3 (42.86)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Lombardo, F; Obach, RS; Waters, NJ1
Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Inoue, T; Kurokawa, K; Nakamura, A; Narita, M; Shiokawa, M; Suzuki, T1
Amano, T; Asato, M; Hashimoto, K; Ikegami, D; Kuzumaki, N; Matsushima, Y; Nakamura, A; Narita, M; Niikura, K; Shiokawa, M; Suzuki, T; Takagi, S; Takei, D; Tsurukawa, Y1
Li, SX; Liu, LJ; Lu, L; Wu, P; Zou, Y1
Aguiar, DC; Almeida-Santos, AF; Duarte, ID; Ferreira, RC; Gobira, PH; Moreira, FA; Romero, TR; Souza, DP1

Reviews

1 review(s) available for aripiprazole and morphine

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

6 other study(ies) available for aripiprazole and morphine

ArticleYear
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
    Bioorganic & medicinal chemistry letters, 2010, Dec-15, Volume: 20, Issue:24

    Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility

2010
Usefulness of the dopamine system-stabilizer aripiprazole for reducing morphine-induced emesis.
    European journal of pharmacology, 2007, Sep-10, Volume: 570, Issue:1-3

    Topics: Analgesics, Opioid; Animals; Antipsychotic Agents; Aripiprazole; Ferrets; Male; Morphine; Piperazines; Quinolones; Receptors, Dopamine D2; Vomiting

2007
Suppression of dopamine-related side effects of morphine by aripiprazole, a dopamine system stabilizer.
    European journal of pharmacology, 2008, Dec-14, Volume: 600, Issue:1-3

    Topics: Analgesics, Opioid; Animals; Antipsychotic Agents; Aripiprazole; Catalepsy; Dopamine; Dopamine Antagonists; Dose-Response Relationship, Drug; Hyperkinesis; Male; Mice; Mice, Inbred ICR; Morphine; Nucleus Accumbens; Piperazines; Prochlorperazine; Quinolones; Reward; Severity of Illness Index

2008
Aripiprazole blocks reinstatement but not expression of morphine conditioned place preference in rats.
    Pharmacology, biochemistry, and behavior, 2009, Volume: 92, Issue:2

    Topics: Animals; Aripiprazole; Conditioning, Classical; Male; Morphine; Piperazines; Quinolones; Rats; Rats, Sprague-Dawley

2009
The antipsychotic aripiprazole selectively prevents the stimulant and rewarding effects of morphine in mice.
    European journal of pharmacology, 2014, Nov-05, Volume: 742

    Topics: Animals; Antipsychotic Agents; Aripiprazole; Central Nervous System Stimulants; Conditioning, Psychological; Disease Models, Animal; Male; Mice; Morphine; Motor Activity; Nociception; Opioid-Related Disorders; Piperazines; Quinolones; Reward

2014